Compare NUCL & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUCL | CRBU |
|---|---|---|
| Founded | 2023 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.4M | 138.3M |
| IPO Year | 2026 | 2021 |
| Metric | NUCL | CRBU |
|---|---|---|
| Price | $4.53 | $0.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 158.9K | ★ 5.0M |
| Earning Date | 10-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $145.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.55 | $0.44 |
| 52 Week High | $14.22 | $3.53 |
| Indicator | NUCL | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 23.81 | 22.79 |
| Support Level | N/A | N/A |
| Resistance Level | $6.45 | $0.58 |
| Average True Range (ATR) | 0.26 | 0.04 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 5.93 | 5.57 |
Eagle Nuclear Energy Corp is a next-generation nuclear energy company that seeks to combine domestic uranium exploration and development with proprietary small modular reactor (SMR) technology. It holds rights to the mineable, measured, and indicated uranium deposit in the United States, known as the Aurora Uranium Project, located in southeastern Oregon. The Aurora Uranium Project includes the Aurora deposit, with an estimated resource of 32.75 million pounds (Indicated) and 4.98 million pounds (Inferred) of near-surface uranium, and the adjacent Cordex zone.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.